In this Issue:
Breast cancer risk factors
Guideline concordant post-treatment care
Long-term cardiac safety of anti-HER2 agents
Trastuzumab-related cardiotoxicity in older patients
Primary G-CSF prophylaxis regimens
IMRT: superior overall cosmesis
QoL impact of SLNB
EndoPredict identifies late distant metastases
Loss of HER2 positivity and prognosis after neoadjuvant therapy
Neoadjuvant therapy in triple-negative or HER2+ disease
Please login below to download this issue (PDF)